

November 15, 2012

Interprotein Corporation

Adoption of small molecule IL-6 inhibitor program of Interprotein as a subject for A-STEP

Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) announced today that Interprotein’s small molecule IL-6 inhibitor program was adopted as a subject (support type: Full-scale R&D Stage, High-risk Challenge) in the first approval of 2012 for A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven R&D) by Japan Science and Technology Agency (JST).

The subjects that were adopted in the first approval of 2012 for A-STEP were listed in:

<http://www.jst.go.jp/a-step/kadai/h24-1honkaku.html> (in Japanese) or
<http://www.jst.go.jp/pr/info/info907/index.html> (in Japanese)

Contact:

Hirotsugu KOMATSU, Ph.D.

Interprotein Corporation

TEL/FAX: +81-(0)42-770-9477

E-mail : info@interprotein.com